Optima Health (AIM:OPT) expects full-year FY26 adjusted EBITDA to be c.10% ahead of market consensus (£18.1m), marking a clear upside to expectations for the year ended 31 March. The upgrade is driven by stronger-than-anticipated H2 trading and a recent acquisition that management says enhances scale and cost efficiency.
The group completed the acquisition of PAM on 26 March. Optima said the deal positions the enlarged business to "capitalise on the growing market opportunity" and will deliver "significant operational and cost synergies" that support its medium-term targets of £200m revenue and £40m adjusted EBITDA.
A previously disclosed procurement matter has been settled. Optima recognised other operating income of £2.3m in H1 FY26 and a further £2.4m in H2 FY26, which it has included in the period’s performance.
"Optima's strong financial performance in H2, ahead of market expectations, reflects the consistent progress we have continued to make against our strategic objectives. The recent transformational acquisition of PAM has further solidified Optima's position in the attractive and growing occupational health market. We look forward to increasing our presence in our core markets, alongside seeking new opportunities, as we continue to accelerate growth," said Jonathan Thomas, Chief Executive Officer.
